The role of oral direct thrombin inhibitors in the prophylaxis of venous thromboembolism

Pharmacotherapy

Volumn 24, Issue 10 I, 2004, Pages

  Hawkins, David ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

Oral direct thrombin inhibitors; Prophylaxis; Pulmonary embolism; Venous thromboembolism; Ximelagatran

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISABILITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG WITHDRAWAL; HEART FAILURE; HEART INFARCTION; HUMAN; IMMOBILIZATION; INTENSIVE CARE UNIT; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; META ANALYSIS; ORTHOPEDIC SURGERY; PATHOPHYSIOLOGY; PREVALENCE; PROPHYLAXIS; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; STROKE; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM; WOUND INFECTION;

ADMINISTRATION, ORAL; AZETIDINES; BENZYLAMINES; CLINICAL TRIALS, PHASE III; DOUBLE-BLIND METHOD; FIBRINOLYTIC AGENTS; HUMANS; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS; THROMBIN; VENOUS THROMBOSIS;

EID: 4644248172     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.15.179S.43158     Document Type: Review

References (25)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med 1991;151:933-8.
2. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-93.
3. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals from the council on thrombosis (in consultation with the council on cardiovascular radiology), American Heart Association. Circulation 1996;93:2212-45.
4. Goldhaber SZ, Visani L, DeRosa M. Acute pulmonary embolism: clinical outcomes in the international cooperation pulmonary embolism registry (ICOPER). Lancet 1999;353:1386-9.
5. Goldhaber S. Pulmonary embolism. N Engl J Med 1998;359:93-104.
6. Bernardi E, Prandoni P. The post-thrombotic syndrome. Curr Opin Pulm Med 2000;6:335-42.
7. Weinmann EE, Salzman EW. Deep-vein thrombosis. N Engl J Med 1994;331:1630-40.
8. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119:132S-75.
9. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-73.
10. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107(23 suppl 1):16-19.
11. Baslin TP, White K, Charles A. Fatal pulmonary embolism in hospitalized medical patients. J Clin Pathol 1997;50:609-10.
12. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG, for the Steering Committee of the Pentasaccharide in Hip Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip fracture surgery. N Engl J Med 2001;345:1298-304.
13. Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999;81:932-40.
14. Rosen SF, Clagett GP. Prevention of venous thromboembolism. Curr Opin Hematol 1999;6:285-90.
15. Goldhaber SZ, Elliott CG. Acute pulmonary embolism, part II: risk stratification, treatment, and prevention. Circulation 2003;108:2834-8.
16. Samama MM, Cohen AT, Darmon Y-E, et al, for the Prophylaxis in Medical Patients with Enoxaparin Study Group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800.
17. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 2003;109:S9-15.
18. EIg M, Gustafsson D, Carlsson, S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 1999;94:187-97.
19. Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip replacement: the METHRO II randomized trial. Lancet 2002;360:1441-7.
20. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO III study. Thromb Haemost 2003;89:288-96.
21. Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003;1(12):2490-6.
22. Colwell CW, Berkowitz SD, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement: a randomized, double-blind study. J Thromb Haemost 2003;10:2119-30.
23. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial. Ann Intern Med 2002;137:648-55.
24. Francis CW, Berkowitz SD, Comp PC, et al, for the EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after knee replacement. N Engl J Med 2003;349:1703-12.
25. Elkeboom JW, Quintan DJ, Douketis J. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomized controlled trials. Lancet 2001;358:9-15.